Peanut butter cookie? Yes, please!
There’s new hope for kids who have multiple food allergies through a treatment that combines a drug with a food desensitization process, according to a study published Dec. 11 in The Lancet Gastroenterology & Hepatology.
The phase-2 clinical trial of 48 children ages 4 to 15 showed that most kids who received the antibody drug omalizumab while consuming gradually increasing doses of problematic foods could tolerate the foods at the end of the nine-month study, conducted at the Sean N. Parker Center for Allergy and Asthma Research at Stanford.
“This could be a very promising way to decrease the burden of living with food allergies,” says senior author Sharon Chinthrajah, MD, a clinical assistant professor of medicine and pediatrics and director of the center’s Clinical Translational Research Unit.